But why would NICE waste precious time and resources on an appraisal for DCVAX, before it was guaranteed that DCVaX was an approved and available option.
It also makes sense to me that an appraisal, once MHRA approved and all submission evidence is in hand, shouldn't really take that long. They are analyzing the cost feasibility. Not 1.7m pages of trial data.
Hence a quick decision by NICE once MHRA approval and evidence e submitted by NWBO.
Market Data 
Markets 
